Study guide

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis

Key Takeaways Explain This Topic AI

Acute uncomplicated cystitis is predominantly caused by uropathogenic Escherichia coli (75%–90%) and Staphylococcus saprophyticus (5%–15%), with diagnosis confirmed by acute dysuria, frequency, urgency, and urinalysis demonstrating leukocyte esterase, nitrites, and pyuria (>5–10 WBC/hpf).

First-line empiric antimicrobials per IDSA guidelines include nitrofurantoin monohydrate/macrocrystals (100 mg BID x 5 days; avoid if eGFR <30 mL/min or at 36–42 weeks gestation), trimethoprim-sulfamethoxazole DS (160/800 mg BID x 3 days; avoid if local resistance >20% or in first trimester and near term), and fosfomycin trometamol (3 g single oral sachet); fluoroquinolones are strictly reserved for complicated infections.

Recurrent UTIs (≥2 culture-confirmed episodes in 6 months or ≥3 in 12 months) warrant non-antimicrobial behavioral modifications, topical vaginal estrogen in postmenopausal women with genitourinary syndrome of menopause (GSM), and postcoital or low-dose daily antimicrobial prophylaxis.

Asymptomatic bacteriuria (ASB, ≥100,000 CFU/mL) requires universal urine culture screening at the initial prenatal visit (12–16 weeks) and mandatory treatment (nitrofurantoin, amoxicillin-clavulanate, or cephalexin) with a test-of-cure culture 1–2 weeks post-treatment to prevent progression to acute pyelonephritis (which occurs in 20%–40% of untreated gravidas).

Acute pyelonephritis presents with fever, rigors, flank pain, and costovertebral angle (CVA) tenderness; pregnant women, patients with intractable vomiting, and those with sepsis signs require mandatory hospital admission for IV broad-spectrum beta-lactams (e.g., ceftriaxone), while microscopic hematuria (≥3 RBCs/hpf) requires excluding transient causes prior to AUA risk-stratified urologic referral.

Last updated: October 2026

Epidemiology & Microbiology of UTIs in Women

Urinary tract infections (UTIs) affect over 50% to 60% of women during their lifetime. Distinct biological and behavioral mechanisms drive this female predisposition:

Anatomical Vulnerability: The female urethra is short (~4 cm compared to ~20 cm in biological males) and terminates in close proximity to the vulvar introitus and perianal region, facilitating the retrograde ascent of enteric bacteria into the bladder.

Sexual Intercourse: Coitus mechanically massages periurethral and introital flora into the bladder lumen. Spermicide use (nonoxynol-9) and diaphragms disrupt the protective lactobacilli of the vaginal microbiota.

Estrogen Deficiency & Menopause: In reproductive-age women, circulating 17-beta-estradiol supports a glycogen-rich vaginal epithelium colonized by Lactobacillus species, maintaining an acidic pH (3.8–4.5) that inhibits Enterobacteriaceae. In postmenopausal women with genitourinary syndrome of menopause (GSM), loss of estrogen causes epithelial atrophy, depletion of lactobacilli, and an elevated vaginal pH (>5.0), facilitating uropathogen colonization.

Microbiology of Uncomplicated UTIs

Uropathogenic Escherichia coli (UPEC): Causes 75% to 90% of uncomplicated cystitis and pyelonephritis cases. UPEC strains express type 1 fimbriae (adhering to bladder uroplakins) and P-fimbriae (binding to renal digalactoside receptors).

Staphylococcus saprophyticus: Coagulase-negative Gram-positive staphylococcus causing 5% to 15% of acute cystitis in young, sexually active women.

Other Enterobacteriaceae: Klebsiella pneumoniae , Proteus mirabilis (urease-producing rod that hydrolyzes urea into ammonia, elevating urine pH >7.5 and promoting struvite calculi), and Enterobacter species.

Gram-Positive Organisms: Enterococcus faecalis occurs primarily in older women, catheterized patients, or those with structural urologic anomalies.

Acute Uncomplicated Cystitis: Presentation & Diagnostic Urinalysis

Acute uncomplicated cystitis is a symptomatic infection confined to the bladder in healthy, non-pregnant, premenopausal females with anatomically normal urinary tracts.

Clinical Presentation

Patients present with acute-onset irritative lower urinary tract symptoms:

Dysuria: Internal urethral or suprapubic burning during micturition.

Frequency & Urgency: Sensation of needing to void small volumes at frequent intervals.

Suprapubic Discomfort: Dull aching or pressure over the lower hypogastrium.

Absence of Vaginal Symptoms: Absence of vaginal discharge, pruritus, or deep dyspareunia yields a high post-test probability (>90%) for true cystitis. If vaginal symptoms coexist, evaluate for vaginitis, cervicitis, or pelvic inflammatory disease (PID).

Urinalysis Interpretation

Evaluate a clean-catch midstream urine specimen to minimize perineal contamination (<5 squamous epithelial cells/hpf indicates an adequate sample):

Leukocyte Esterase (LE): Enzyme released by activated neutrophils indicating pyuria (sensitivity 75%–90%, specificity ~95%).

Nitrites: Gram-negative enteric rods reduce dietary nitrates to nitrites. Highly specific (>95%), but sensitivity is 50%–60% because bacterial incubation requires ~4 hours in the bladder. False negatives occur with Gram-positive pathogens ( S. saprophyticus , Enterococcus ) or frequent voiding.

Microscopic Pyuria: >5 to 10 WBC/hpf on centrifuged urine; present in nearly all genuine UTIs.

Microscopic Hematuria: Present in ~30% of acute uncomplicated cystitis episodes due to mucosal capillary friability; resolves within 4 to 6 weeks following infection clearance.

Note

In healthy, non-pregnant premenopausal women presenting with classic acute dysuria and frequency without vaginal discharge, empiric therapy can be initiated without a pre-treatment urine culture. Urine culture and susceptibility testing are mandatory for suspected pyelonephritis, recurrent UTIs, pregnancy, treatment failure, or complicated hosts.

First-Line Antimicrobial Regimens & Antimicrobial Stewardship

The Infectious Diseases Society of America (IDSA) establishes evidence-based first-line regimens for acute uncomplicated cystitis to balance clinical cure against ecological collateral damage (multidrug resistance and C. difficile colitis).

Antimicrobial Agent Standard Dosing & Duration Mechanism & Spectrum Gestational & Renal Caveats Common Adverse Effects

Nitrofurantoin Monohydrate / Macrocrystals (Macrobid) 100 mg PO BID x 5 days Reduced by bacterial flavoproteins into active intermediates attacking ribosomal proteins, DNA, and RNA. High urinary concentration with minimal systemic tissue levels. Avoid if eGFR <30 mL/min/1.73 m² (inadequate urine concentration). Avoid near term ( 36–42 weeks ) due to risk of neonatal hemolytic anemia. Nausea, headache, anorexia, dark urine; rare pulmonary toxicity or peripheral neuropathy with prolonged use.

Trimethoprim-Sulfamethoxazole DS (TMP-SMX 160/800 mg) 1 DS tablet PO BID x 3 days Sequential blockade of bacterial folic acid synthesis. High urinary and tissue concentrations. First-line ONLY if local E. coli resistance is <20% . Contraindicated in 1st trimester (folate antagonism) and near term (kernicterus). Rash, photosensitivity, hyperkalemia, gastrointestinal upset, blood dyscrasias.

Fosfomycin Trometamol 3 g PO single-dose sachet dissolved in cold water Inactivates enolpyruvyl transferase (MurA), blocking peptidoglycan cell wall synthesis. Safe across all trimesters of pregnancy. No dosage adjustment required in mild-to-moderate renal insufficiency. Diarrhea, headache, nausea; slightly lower clinical cure rate than 5-day nitrofurantoin.

Important

Fluoroquinolones (Ciprofloxacin, Levofloxacin): Fluoroquinolones are strictly reserved for complicated infections, pyelonephritis, or when first-line agents cannot be used . The FDA and IDSA issue explicit warnings restricting fluoroquinolones due to severe boxed warnings: tendonitis and tendon rupture (Achilles tendon), QT prolongation, peripheral neuropathy, central nervous system toxicities, glycemic dysregulation, and aortic aneurysm rupture, alongside high rates of collateral resistance.

Recurrent Urinary Tract Infections (rUTI)

Recurrent UTI is defined as ≥2 culture-confirmed symptomatic episodes within 6 months , or ≥3 culture-confirmed episodes within 12 months .

Non-Antimicrobial & Prophylactic Strategies

Hydration: Consuming an additional 1.5 L of water daily reduces UTI recurrence by nearly 50% via continuous mechanical flushing of the bladder.

Postcoital Voiding: Promotes rapid hydrodynamic clearance of bacteria inoculated during intercourse.

Cranberry Proanthocyanidins (PACs): Standardized cranberry extract (36 mg soluble PACs daily) inhibits P-fimbriated E. coli adherence to uroepithelial receptors.

Topical Vaginal Estrogen: In postmenopausal women with GSM, low-dose topical vaginal estrogen (estradiol cream 0.5 g, estradiol 10 mcg tablet, or estradiol vaginal ring) is the most effective non-antimicrobial strategy . It reverses mucosal atrophy, restores lactobacilli, lowers vaginal pH to <4.5, and reduces recurrence by over 60%. (Oral hormone therapy does not replicate this benefit).

Antimicrobial Prophylaxis: When non-pharmacologic measures fail, postcoital single-dose prophylaxis (nitrofurantoin 50–100 mg, TMP-SMX SS 80/400 mg, or cephalexin 250 mg within 2 hours of intercourse) or continuous daily low-dose prophylaxis (nitrofurantoin 50 mg at bedtime for 6–12 months) may be prescribed after confirming eradication of prior infection.

Asymptomatic Bacteriuria (ASB) in Pregnancy: Universal Screening & Treatment

Asymptomatic bacteriuria is defined as the isolation of ≥100,000 CFU/mL of a single uropathogen from a clean-catch midstream urine specimen in an individual without urinary symptoms .

Universal Screening Mandate

In non-pregnant women, ASB is benign and must never be screened or treated. In pregnancy, universal screening is mandatory :

Timing: Screen all gravidas with a clean-catch urine culture at the initial prenatal visit ( 12 to 16 weeks gestation ). Urine dipstick and microscopy have low sensitivity and cannot substitute for quantitative culture.

Gestational Risks: Progesterone-induced ureteral smooth muscle relaxation produces peristaltic hypomotility, hydroureter, and urinary stasis, while the enlarging dextrorotated gravid uterus mechanically compresses the ureters. Consequently, 20% to 40% of untreated gravidas with ASB progress to acute pyelonephritis , leading to septic shock, acute respiratory distress syndrome (ARDS), preterm labor, and low birth weight.

Gestational Regimens: Treat with a 5- to 7-day course of pregnancy-compatible antimicrobials: cephalexin 500 mg PO TID/QID x 5–7 days, amoxicillin-clavulanate 500/125 mg PO BID x 5–7 days, or nitrofurantoin 100 mg PO BID x 5–7 days (safe in second trimester; avoid at 36–42 weeks).

Mandatory Test-of-Cure: Obtain a follow-up urine culture 1 to 2 weeks post-treatment completion , followed by monthly screening cultures throughout pregnancy.

Acute Pyelonephritis: Triage, Inpatient Criteria & Treatment

Acute pyelonephritis is an invasive infection of the renal parenchyma and renal pelvis, ascending from the lower urinary tract.

Clinical Presentation & Diagnostics

Clinical Triad: Systemic fever (>38.0°C / 100.4°F), rigors/chills, and unilateral or bilateral flank pain / costovertebral angle (CVA) tenderness, accompanied by nausea, vomiting, and anorexia.

Urinalysis: Pyuria, bacteriuria, and white blood cell (WBC) casts (pathognomonic for renal parenchymal inflammation, differentiating pyelonephritis from lower tract cystitis).

Triage & Admission Criteria

Outpatient Oral Management: Reserved strictly for mild, uncomplicated cases in reliable, non-pregnant, immunocompetent, hemodynamically stable patients tolerating oral fluids with reliable follow-up. Regimen: oral ciprofloxacin 500 mg PO BID x 7 days or levofloxacin 750 mg PO daily x 5 days , preceded by an initial dose of IV ceftriaxone 1 g in clinic if local fluoroquinolone resistance exceeds 10%.

Mandatory Inpatient Admission Criteria:

ALL pregnant women (due to high risks of sepsis, ARDS, and preterm labor).

Inability to tolerate oral hydration or medications (intractable vomiting).

Hemodynamic instability, persistent tachycardia, hypotension, or septic signs.

High persistent fever (>38.5°C), severe unremitting pain, or toxic appearance.

Suspected urinary tract obstruction or nephrolithiasis.

Significant renal impairment or severe immunocompromise.

Inpatient Regimen: IV ceftriaxone 1 g every 24 hours , ampicillin plus gentamicin, or cefepime. Continue parenteral therapy until afebrile for 24 to 48 hours , then transition to an oral agent based on susceptibilities to complete a 10- to 14-day total antimicrobial course .

Microscopic Hematuria Workup in Women

Microscopic hematuria is defined by the American Urological Association (AUA) as ≥3 red blood cells per high-power field (RBCs/hpf) on microscopic examination of a centrifuged clean-catch urine specimen. Positive chemical dipsticks require microscopic confirmation.

Stepwise Clinical Evaluation

Exclude Benign / Transient Causes: Active menses (repeat UA after menses clears or obtain a catheterized specimen), vigorous exercise within 48 hours, sexual intercourse, trauma, or acute UTI.

Evaluate & Treat UTI: If pyuria and bacteriuria accompany hematuria, treat the infection and repeat urinalysis with microscopy 6 weeks post-treatment to confirm complete clearance.

AUA Risk Stratification & Referral: If microscopic hematuria (≥3 RBCs/hpf) persists without identifiable transient causes, stratify into low, intermediate, or high risk based on age (>50 years), smoking history (pack-years), and degree of hematuria (>25 RBCs/hpf). Intermediate- and high-risk patients warrant urology referral for cystoscopy and multiphasic CT urography to evaluate for urothelial and renal malignancy.

Nephrolithiasis (Renal Stones)

Kidney stones affect roughly 1 in 11 U.S. adults. About 70%–80% are calcium oxalate ; struvite (magnesium ammonium phosphate) stones form in alkaline urine infected with urease-producing organisms such as Proteus and are relatively more common in women because of their higher UTI rate.

Presentation: Sudden colicky flank pain radiating to the groin or labia, nausea, and hematuria (present in most cases). Fever with an obstructing stone is a urologic emergency : an infected, obstructed kidney needs urgent decompression (stent or nephrostomy) plus antibiotics.

Imaging: Low-dose noncontrast CT is the reference test outside pregnancy. In pregnancy, start with renal ultrasound; MRI or low-dose CT is a second step if needed.

Acute management: NSAIDs are first-line analgesics (avoid NSAIDs in pregnancy after about 20 weeks), plus antiemetics and hydration. Most stones ≤5 mm pass spontaneously; the AUA supports an alpha-blocker such as tamsulosin as medical expulsive therapy for distal ureteral stones ≤10 mm. Refer for stones >10 mm, infection, acute kidney injury, a solitary kidney, or uncontrolled pain.

Prevention: Drink enough to produce more than 2.5 L of urine daily, keep normal dietary calcium (1,000–1,200 mg/day; low-calcium diets raise oxalate absorption), limit sodium and animal protein, and send a recovered stone for analysis. A 24-hour urine study guides thiazides (hypercalciuria) or potassium citrate (hypocitraturia).